·Î°©ÊÇ·¢²¡ÂÊ×î¸ßµÄÖ×Áö£¬Ñо¿Åú×¢£¬·Î°©µÄÔçÆÚɸ²éºÍÕï¶ÏÄܹ»¼«´óµÄÌá¸ßÎåÄêÉúÑÄÂÊ¡£Cancers(Basel)½ÒÏþһƪÌâΪNon-Invasive Biomarkers for Early Lung Cancer DetectionµÄ×ÛÊö£¬ÖÜÈ«ÏÈÈÝÁ˷ΰ©ÔçɸÉúÎï±ê¼ÇÎïµÄÑо¿Ï£Íû¡£

±¾Æª×ÛÊöÊ×ÏÈÌá³ö£¬ÀíÏëµÄÖ×ÁöÉúÎï±ê¼ÇÎïÓ¦¸Ã¾ßÓÐÒÔÏÂÌØÕ÷£º
(1) Çå¾²¡¢Ò×ÓÚÊÕÂ޺ͼì²â£¬¾ßÓб¾Ç®Ð§Ò棻
(2) ²»ÊÜÐÔ±ð»òÖÖ×åµÈÖ÷ÒªÉú³Ýͳ¼ÆÊý¾ÝµÄÓ°Ï죻
(3) ¸ßѸËÙ¶È¿É׼ȷ·¢Ã÷ÔçÆÚ°©Ö¢£»
(4) ×îÉÙµÄÈËÁ¦Í¶Èë£¬ÌØÊâÊÇ´ó×ÚÊý¾ÝµÄÆÊÎö£¬ÒÔïÔ̶ÔÈËÁ¦×ÊÔ´µÄÓ°Ïì¡£
Ðí¶à·ÇÇÖÈëÐÔÉúÎï±ê¼ÇÎÈçctDNA¡¢CTC¡¢ÂѰ×ÖÊ¡¢Ö¬ÖÊ¡¢RNAºÍmicroRNA£¨miRNA£©£¬¿ÉÒÔÔÚѪ½¬¡¢ÑªÇå¡¢ÄòÒº¡¢ÍÙÒº¡¢¸¹Ë®ºÍÄÔ¼¹ÒºµÈÌåÒºÖмì²âµ½¡£ÕâЩÉúÎï±ê¼ÇÎï±»ÆÕ±éÑо¿£¬È»¶ø£¬ÓÉÓÚ»ùÒò×éµÄ²»ÎȹÌÐÔ£¬ÒÔ¼°·Î°©Ï¸°ûµÄÒ»Á¬Ñݱ䣬ÉúÎï±ê¼ÇÎïµÄ±í´ï»áÓкܴóµÄת±ä£¬ÀíÏëµÄÉúÎï±ê¼ÇÎïÉÐδ·¢Ã÷¡£
DNA¼×»ù»¯
·Î°©±í¹ÛÒÅ´«×ª±äÊdz£¼ûµÄ£¬Ñª½¬ÖÐDNA¼×»ù»¯µÄ¼ì²â£¬×÷Ϊɸ²éºÍÕï¶Ï·Î°©µÄ°×±ê¼ÇÎҲÏÔʾ³öÔ¶¾°¡£BearzattoµÈÈ˱¨µÀÁËp16INK4A¼×»ù»¯ÔÚÔçÆÚÏÙ°©Ñª½¬Ñù±¾ÖÐÆµÂÊÔöÌí¡£Í¬Ñù£¬ÑªÒºÑù±¾Öмì²âµ½µÄRASSF1AºÍCDKN2A¼×»ù»¯ÔÚÔçÆÚ·Î°©Öо³£±»·¢Ã÷£¬¾Ý±¨µÀÃô¸ÐÐÔΪ22%ÖÁ66%£¬ÌØÒìÐÔΪ57-100%¡£
microRNA(miRNA)
miRNAÊdz¤¶ÈΪ18-25¸öºËÜÕËáµÄСÐͷDZàÂëRNA£¬¼ÓÈë»ùÒò±í´ïת¼ºóµ÷¿Ø¡£ËüÃÇÔÚ°üÀ¨°©Ö¢ÔÚÄÚµÄÐí¶à²¡ÀíÌõ¼þÏÂÒì³£±í´ï£¬²¢ÇÒ¿ÉÒÔÔÚÄòÒº¡¢ÌµÒººÍѪҺÖмì²âµ½£¬Ê¹ËüÃdzÉΪ°©Ö¢¼ì²âµÄÉúÎï±ê¼ÇÎï¡£miRNA¿ÉÒÔ×÷ΪÖ×ÁöÒÖÖÆÒò×Ó»ò°©»ùÒò£¬ÉõÖÁÁ½Õß¼æ¶øÓÐÖ®¡£±ðµÄ£¬miRNAÔÚ°©Ö¢±¬·¢Éú³¤µÄÕû¸öÀú³ÌÖмá³ÖÎȹÌÐÔ£¬ÓÉÓÚËüÃÇ̫С¶øÎÞ·¨½µ½â£¬²¢ÇÒһЩmiRNAÔÚÍâÃÚÌåÖнøÒ»²½Êܵ½±£»¤¡£Òò´Ë£¬miRNA±»ÒÔΪÊǰ©Ö¢Õï¶ÏºÍ¼à²âµÄÒ»¸öÓÐÎüÒýÁ¦µÄÉúÎï±ê¼ÇÎï¡£
ÔÚYanaiharaµÈÈ˵ÄÔçÆÚÑо¿ÖУ¬miR-17-3p¡¢miR-21¡¢miR-106a¡¢miR-146¡¢miR-155¡¢miR-191¡¢miR-192¡¢miR-203¡¢miR-205¡¢miR-210¡¢miR-212ºÍmiR-214µÈ12ÖÖmicroRNAÔÚ²î±ðµÄ¶ñÐÔ×éÖ¯Öбí´ï²î±ð£¬±»ÅжÏÎªÇø·Ö·Î°©ºÍÁ¼ÐÔ·Î×éÖ¯µÄDZÔÚÉúÎï±ê¼ÇÎï¡£WozniakµÈÈ˵ÄÁíÒ»ÏîÑо¿Åú×¢£¬24ÖÖmiRNAµÄ×éºÏÄܹ»½«·Î°©²¡ÀýÓ뿵½¡±ÈÕÕÇøÍÑÀëÀ´¡£×÷ÕßÒÔΪ£¬ÉÏÊömiRNAÔÚѪ½¬ÖеĹý±í´ï¿É×÷ΪÔçÆÚ¼ì²âNSCLCµÄÉúÎï±ê¼ÇÎֵµÃ½øÒ»²½Ñо¿¡£
ctDNA
ctDNA£¨Ñ»·Ö×ÁöDNA£©°üÀ¨ÑªÒº»òÆäËûÌåÒºÖб»°ü¹üµÄ£¨ÔÚÑ»·ÄÒÅÝÖУ©ºÍδ±»°ü¹üµÄÓÎÀëDNA£¬ctDNAÊÇÒ»ÖÖºÜÓÐǰ;µÄÉúÎï±ê¼ÇÎï¡£

ͼ1 ctDNAºÍ×éÖ¯»î¼ìµÄÖ÷񻂿±ð
×îºó£¬±¾Æª×ÛÊöÖ¸³ÊÏÖÔÚ¿ª·¢ÓÐÓúͿɿ¿µÄÖ×ÁöÉúÎï±ê¼ÇÎï±£´æµÄÌôÕ½£º
(1) ȱ·¦“ÀíÏëµÄ”ÉúÎï±ê¼ÇÎï×÷Ϊ½ð±ê×¼£¬Ê¹µÃÑé֤еÄÉúÎï±ê¼ÇÎïÒÔÓÐÓÃÕï¶Ï°©Ö¢£¬¼´½¨ÉèÁÙ´²Ïà¹ØÐÔºÍÊÊÓÃÐÔ¾ßÓÐÌôÕ½ÐÔ¡£
(2) Ö×Áö½ø»¯²»¿É×èÖ¹µØµ¼ÖÂÍ»±ä¶àÑùÐÔ£¬µ¼ÖÂÖ×Áö¼äºÍÖ×ÁöÄÚµÄÒìÖÊÐÔ£¬´Ó¶øµ¼ÖÂÌØ¶¨Ô·¢Ö×ÁöÖÐÉúÎï±ê¼ÇÎïµÄת±ä¡£
(3) ÉúÎï±ê¼ÇÎïµÄÖØ´óÐԺͶ¯Ì¬×ª±ä£¨ÌØÊâÊÇÔÚѪ½¬ÖУ©Ê¹µÃÔÚͳһ»¼ÕßÖлòÔÚ»¼ÕßÖ®¼ä¾ÙÐнÏÁ¿Ê±ºÜÊÇÄÑÌâ¡£
(4) Ðí¶àÌØÒìÐÔÉúÎï±ê¼ÇÎïµÄÏà¶ÔƷò½ÏµÍ£¬Í¨³£»áµ¼Ö¼ÙÒõÐÔЧ¹û£¬Òò´ËÌØÒìÐԽϵ͡£
(5) ÑùÆ·ÍøÂç¡¢Öü´æ¡¢ÔËÊäºÍÊÖÒÕÖеıäÁ¿£¬¿ÉÄܵ¼ÖÂЧ¹û·×ÆçÖ£¬¶ÔÉúÎï±ê¼ÇÎïµÄÓÐÓÃÐԺͿɿ¿ÐÔ±¬·¢µ¹ÔËÓ°Ïì¡£
(6) ÓëÐÂÒ©¿ª·¢ÃæÁÙµÄÌôÕ½ÀàËÆ£¬°©Ö¢ÐÂÉúÎï±ê¼ÇÎïµÄ¿ª·¢Éæ¼°´ÓʵÑéÊÒ¹âÁÙ´²µÄÖØ´ó¡¢Âþ³¤ÇÒÌÚ¹óµÄ·¾¶¡£
²Î¿¼ÎÄÏ×
Cancers (Basel). 2022 Nov 24; 14(23): 5782. doi: 10.3390/cancers14235782.













































ÔÁ¹«Íø°²±¸ 44030602000441ºÅ 